Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 3/20 | 0.36 |
| ▸ | MMP1 | P03956 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18705063 | 0.83 | MMP9 (0.33) | MMP9MMP1MMP13MMP2MMP3 | |
| SCHEMBL20069560 | 0.80 | CYP2D6 (0.35) | MMP9MMP1MMP13MAPTCYP2D6 | |
| SCHEMBL20201374 | 0.80 | MMP1 (0.32) | MMP9MMP1MMP13CYP2D6 | |
| SCHEMBL20147468 | 0.79 | RET (0.34) | MMP9MMP1MMP13CYP2D6 | |
| SCHEMBL20148046 | 0.79 | RET (0.34) | MMP9MMP1MMP13CYP2D6 | |
| SCHEMBL16304087 | 0.78 | DRD2 (0.37) | MMP9MMP1MMP13MMP2MMP3 | |
| SCHEMBL20147362 | 0.77 | DPP4 (0.35) | MMP9MMP1MMP13MAPTCYP2D6 | |
| SCHEMBL20147381 | 0.76 | PARP1 (0.33) | MMP9MMP1MMP13CYP2D6 | |
| SCHEMBL20147470 | 0.75 | RET (0.39) | MMP9MMP1MMP13MMP2MMP3 | |
| SCHEMBL20069778 | 0.75 | RET (0.36) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | MMP9 4196/4885MMP1 3562/4885MMP13 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.